{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:15:14Z","timestamp":1788279314715,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00980-6","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:43:09Z","timestamp":1786412589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-L1+ exosomes as biomarkers and therapeutic targets in multiple myeloma: implications for CAR-T efficacy and combination immunotherapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Peng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Xuan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hua","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"1","key":"980_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Primers. 2024;10(1):45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"980_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"issue":"10272","key":"980_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","journal-title":"Lancet"},{"key":"980_CR4","doi-asserted-by":"publisher","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670\u201377. https:\/\/doi.org\/10.1016\/S2352-3026(22)00165-X.","DOI":"10.1016\/S2352-3026(22)00165-X"},{"issue":"19","key":"980_CR5","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1182\/blood.2020008734","volume":"139","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Terpos E, Dimopoulos MA. How I treat relapsed multiple myeloma. Blood. 2022;139(19):2904\u201317. https:\/\/doi.org\/10.1182\/blood.2020008734.","journal-title":"Blood"},{"issue":"8","key":"980_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"issue":"10297","key":"980_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"issue":"11","key":"980_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2213614.","journal-title":"N Engl J Med"},{"issue":"6","key":"980_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","volume":"3","author":"KM Dhodapkar","year":"2022","unstructured":"Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 2022;3(6):490\u2013501. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0018.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"980_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J. CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 2024;14(1):206. https:\/\/doi.org\/10.1038\/s41408-024-01191-8.","journal-title":"Blood Cancer J"},{"issue":"7","key":"980_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transplant Cellular Ther. 2023;29(7):418\u201328. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.007.","journal-title":"Transplant Cellular Ther"},{"issue":"13","key":"980_CR12","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024;8(13):3562\u201375. https:\/\/doi.org\/10.1182\/bloodadvances.2023012416.","journal-title":"Blood Adv"},{"issue":"1","key":"980_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12185-025-04110-0","volume":"124","author":"J Bai","year":"2026","unstructured":"Bai J, Nishimura N, Kawano Y. Advances in immune microenvironment profiling during multiple myeloma progression and therapy. Int J Hematol. 2026;124(1):38\u201347. https:\/\/doi.org\/10.1007\/s12185-025-04110-0.","journal-title":"Int J Hematol"},{"issue":"22","key":"980_CR14","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1182\/bloodadvances.2022007217","volume":"6","author":"C Schinke","year":"2022","unstructured":"Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, et al. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022;6(22):5873\u201383. https:\/\/doi.org\/10.1182\/bloodadvances.2022007217.","journal-title":"Blood Adv"},{"issue":"13","key":"980_CR15","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","volume":"26","author":"N Alrasheed","year":"2020","unstructured":"Alrasheed N, Lee L, Ghorani E, Henry JY, Conde L, Chin M, et al. Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma. Clin Cancer Res. 2020;26(13):3443\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1714.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"980_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41420-024-01818-6","volume":"10","author":"L Xu","year":"2024","unstructured":"Xu L, Wen C, Xia J, Zhang H, Liang Y, Xu X. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. Cell Death Discov. 2024;10(1):55. https:\/\/doi.org\/10.1038\/s41420-024-01818-6.","journal-title":"Cell Death Discov"},{"key":"980_CR17","doi-asserted-by":"publisher","unstructured":"Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e459\u201369. https:\/\/doi.org\/10.1016\/S2352-3026(19)30110-3.","DOI":"10.1016\/S2352-3026(19)30110-3"},{"issue":"2","key":"980_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.clml.2024.08.004","volume":"25","author":"R Chakrabarti","year":"2025","unstructured":"Chakrabarti R, Siegel D, Biran N. The evolving role of checkpoint inhibitors in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2025;25(2):96\u2013108. https:\/\/doi.org\/10.1016\/j.clml.2024.08.004.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"980_CR19","doi-asserted-by":"publisher","first-page":"1640168","DOI":"10.3389\/fimmu.2025.1640168","volume":"16","author":"D Soncini","year":"2025","unstructured":"Soncini D, Marimpietri D, Ladisa F, Lai F, Airoldi I, Gramignoli R, et al. Bone marrow-derived extracellular vesicles from multiple myeloma patients promote adaptive immune dysfunction via HLA-G, PD-1, and PD-L1. Front Immunol. 2025;16:1640168. https:\/\/doi.org\/10.3389\/fimmu.2025.1640168.","journal-title":"Front Immunol"},{"key":"980_CR20","doi-asserted-by":"publisher","first-page":"1603855","DOI":"10.3389\/fimmu.2025.1603855","volume":"16","author":"T Kansha","year":"2025","unstructured":"Kansha T, Ma X, Wang H, Yu X, Song Y, Guo Z, et al. Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy. Front Immunol. 2025;16:1603855. https:\/\/doi.org\/10.3389\/fimmu.2025.1603855.","journal-title":"Front Immunol"},{"issue":"8","key":"980_CR21","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","volume":"186","author":"R Kalluri","year":"2023","unstructured":"Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer. Cell. 2023;186(8):1610\u201326. https:\/\/doi.org\/10.1016\/j.cell.2023.03.010.","journal-title":"Cell"},{"issue":"11","key":"980_CR22","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s12276-024-01340-w","volume":"56","author":"Z Ye","year":"2024","unstructured":"Ye Z, Li G, Lei J. Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics. Exp Mol Med. 2024;56(11):2365\u201381. https:\/\/doi.org\/10.1038\/s12276-024-01340-w.","journal-title":"Exp Mol Med"},{"issue":"7","key":"980_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/cimb47070525","volume":"47","author":"LD Dragu","year":"2025","unstructured":"Dragu LD, Chivu-Economescu M, Pitica IM, Matei L, Bleotu C, Diaconu CC, et al. Targeting exosomal PD-L1 as a new frontier in cancer immunotherapy. CIMB. 2025;47(7):525. https:\/\/doi.org\/10.3390\/cimb47070525.","journal-title":"CIMB"},{"issue":"3","key":"980_CR24","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/jcp.30645","volume":"237","author":"SZ Rasihashemi","year":"2022","unstructured":"Rasihashemi SZ, Rezazadeh Gavgani E, Majidazar R, Seraji P, Oladghaffari M, Kazemi T, et al. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy. J Cellular Physiol. 2022;237(3):1648\u201360. https:\/\/doi.org\/10.1002\/jcp.30645.","journal-title":"J Cellular Physiol"},{"issue":"9","key":"980_CR25","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s00277-023-05259-6","volume":"102","author":"P Xu","year":"2023","unstructured":"Xu P, Liu J, Chen H, Shang L, Wang F, Zhu Y, et al. Clinical significance of plasma PD-L1+ exosomes in the management of diffuse large B cell lymphoma. Ann Hematol. 2023;102(9):2435\u201344. https:\/\/doi.org\/10.1007\/s00277-023-05259-6.","journal-title":"Ann Hematol"},{"issue":"23","key":"980_CR26","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood.2021014749","volume":"140","author":"E Menu","year":"2022","unstructured":"Menu E, Vanderkerken K. Exosomes in multiple myeloma: from bench to bedside. Blood. 2022;140(23):2429\u201342. https:\/\/doi.org\/10.1182\/blood.2021014749.","journal-title":"Blood"},{"issue":"7","key":"980_CR27","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/cas.70099","volume":"116","author":"S Hagiwara","year":"2025","unstructured":"Hagiwara S, Ri M, Ebina T, Marumo Y, Nakamura T, Hirade K, et al. Immunosuppressive effects of multiple myeloma-derived extracellular vesicles through T cell exhaustion. Cancer Sci. 2025;116(7):1861\u201370. https:\/\/doi.org\/10.1111\/cas.70099.","journal-title":"Cancer Sci"},{"key":"980_CR28","doi-asserted-by":"publisher","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"issue":"23","key":"980_CR29","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","volume":"5","author":"Y Wang","year":"2021","unstructured":"Wang Y, Li C, Xia J, Li P, Cao J, Pan B, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood Adv. 2021;5(23):5290\u201399. https:\/\/doi.org\/10.1182\/bloodadvances.2021004603.","journal-title":"Blood Adv"},{"key":"980_CR30","doi-asserted-by":"publisher","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10):e521\u201329. https:\/\/doi.org\/10.1016\/S2352-3026(19)30115-2.","DOI":"10.1016\/S2352-3026(19)30115-2"},{"issue":"4","key":"980_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"980_CR32","doi-asserted-by":"publisher","unstructured":"Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. CP Cell Biol. 2006, Chapter, 3: Unit 3 22.30(1). https:\/\/doi.org\/10.1002\/0471143030.cb0322s30.","DOI":"10.1002\/0471143030.cb0322s30"},{"issue":"8034","key":"980_CR33","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng B, Bai Z, Zhou X, Zhao Y, Xie YQ, Huang X, et al. The type 2 cytokine fc\u2013IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature. 2024;634(8034):712\u201320. https:\/\/doi.org\/10.1038\/s41586-024-07962-4.","journal-title":"Nature"},{"key":"980_CR34","doi-asserted-by":"publisher","unstructured":"Lee M, Im SK, Baek S, Ji M, Kim M, Lee EJ, et al. rhIL-7-hyFc and hIL-2\/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors. J Immunother Cancer. 2024;12(3):e008001. https:\/\/doi.org\/10.1136\/jitc-2023-008001.","DOI":"10.1136\/jitc-2023-008001"},{"key":"980_CR35","doi-asserted-by":"publisher","unstructured":"Fang R, Huang B, Li Y, Cai Z, Deng Y, Cen X, et al. PD-L1 on tumor-derived extracellular vesicles induces CD8 + T cell terminal exhaustion and mediates anti-PD-1 resistance in head and neck squamous cell carcinoma. Adv Sci (Weinh)Adv Sci. 2026;13(4):e16348. https:\/\/doi.org\/10.1002\/advs.202516348.","DOI":"10.1002\/advs.202516348"},{"issue":"11","key":"980_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41408-018-0139-7","volume":"8","author":"S Faict","year":"2018","unstructured":"Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 2018;8(11):105. https:\/\/doi.org\/10.1038\/s41408-018-0139-7.","journal-title":"Blood Cancer J"},{"issue":"21","key":"980_CR37","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/bloodadvances.2019000403","volume":"3","author":"T Umezu","year":"2019","unstructured":"Umezu T, Imanishi S, Yoshizawa S, Kawana C, Ohyashiki JH, Ohyashiki K. Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion. Blood Adv. 2019;3(21):3228\u201340. https:\/\/doi.org\/10.1182\/bloodadvances.2019000403.","journal-title":"Blood Adv"},{"key":"980_CR38","doi-asserted-by":"publisher","unstructured":"Li G, Wang G, Chi F, Jia Y, Wang X, Mu Q, et al. Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer. J Immunother Cancer. 2021;9(3):e002218. https:\/\/doi.org\/10.1136\/jitc-2020-002218.","DOI":"10.1136\/jitc-2020-002218"},{"issue":"1","key":"980_CR39","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12885-023-10811-8","volume":"23","author":"SJ Park","year":"2023","unstructured":"Park SJ, Park JY, Shin K, Hong TH, Lee M, Kim Y, et al. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer. BMC Cancer. 2023;23(1):389. https:\/\/doi.org\/10.1186\/s12885-023-10811-8.","journal-title":"BMC Cancer"},{"key":"980_CR40","doi-asserted-by":"publisher","first-page":"1097117","DOI":"10.3389\/fimmu.2022.1097117","volume":"13","author":"S Akbar","year":"2023","unstructured":"Akbar S, Raza A, Mohsin R, Kanbour A, Qadri S, Parray A, et al. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer patients. Front Immunol. 2023;13:1097117. https:\/\/doi.org\/10.3389\/fimmu.2022.1097117.","journal-title":"Front Immunol"},{"issue":"2","key":"980_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/17520363.2024.2448117","volume":"19","author":"S Hu","year":"2025","unstructured":"Hu S, Huang F, Li X. Clinicopathological and prognostic significance of exosomal PD-L1 in cancer therapy. Biomark Med. 2025;19(2):51\u201357. https:\/\/doi.org\/10.1080\/17520363.2024.2448117.","journal-title":"Biomark Med"},{"issue":"2","key":"980_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/biomedicines13020500","volume":"13","author":"NE Kushlinskii","year":"2025","unstructured":"Kushlinskii NE, Kovaleva OV, Gratchev AN, Alferov AA, Kuzmin YB, Sokolov NY, et al. Assessing the clinical relevance of soluble PD-1 and PD-L1: a multi-cohort study across diverse tumor types and prognostic implications. Biomedicines. 2025;13(2):500. https:\/\/doi.org\/10.3390\/biomedicines13020500.","journal-title":"Biomedicines"},{"issue":"1","key":"980_CR43","doi-asserted-by":"publisher","first-page":"16460","DOI":"10.1038\/s41598-021-95902-x","volume":"11","author":"MH Young","year":"2021","unstructured":"Young MH, Pietz G, Whalen E, Copeland W, Thompson E, Fox BA, et al. Immunomodulation by durvalumab and pomalidomide in patients with relapsed\/refractory multiple myeloma. Sci Rep. 2021;11(1):16460. https:\/\/doi.org\/10.1038\/s41598-021-95902-x.","journal-title":"Sci Rep"},{"issue":"38","key":"980_CR44","doi-asserted-by":"publisher","first-page":"62490","DOI":"10.18632\/oncotarget.11519","volume":"7","author":"SY Huang","year":"2016","unstructured":"Huang SY, Lin HH, Lin CW, Li CC, Yao M, Tang JL, et al. Soluble PD-L1: a biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget. 2016;7(38):62490\u2013502. https:\/\/doi.org\/10.18632\/oncotarget.11519.","journal-title":"Oncotarget"},{"issue":"4","key":"980_CR45","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/life15040626","volume":"15","author":"D Dragu","year":"2025","unstructured":"Dragu D, Necula LG, Bleotu C, Diaconu CC, Chivu-Economescu M. Soluble PD-L1: from immune evasion to cancer therapy. Life (Basel). 2025;15(4):626. https:\/\/doi.org\/10.3390\/life15040626.","journal-title":"Life (Basel)"},{"issue":"2","key":"980_CR46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/14737159.2023.2178902","volume":"23","author":"TL Whiteside","year":"2023","unstructured":"Whiteside TL. Evaluating tumor cell- and T cell-derived extracellular vesicles as potential biomarkers of cancer and immune cell competence. Expert Rev Mol Diagn. 2023;23(2):109\u201322. https:\/\/doi.org\/10.1080\/14737159.2023.2178902.","journal-title":"Expert Rev Mol Diagn"},{"issue":"4","key":"980_CR47","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","volume":"24","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24(4):896\u2013905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2664.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"980_CR48","doi-asserted-by":"publisher","first-page":"101353","DOI":"10.1016\/j.adro.2023.101353","volume":"9","author":"K Tamari","year":"2024","unstructured":"Tamari K, Minami K, Tatekawa S, Seo Y, Fukusumi T, Tanaka H, et al. Circulating plasma exosomal PD-L1 predicts prognosis of head and neck squamous cell carcinoma after radiation therapy. Adv Radiat Oncol. 2024;9(2):101353. https:\/\/doi.org\/10.1016\/j.adro.2023.101353.","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"980_CR49","doi-asserted-by":"publisher","first-page":"6952","DOI":"10.1038\/s41598-023-33128-9","volume":"13","author":"K Shin","year":"2023","unstructured":"Shin K, Kim J, Park SJ, Lee MA, Park JM, Choi MG, et al. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy. Sci Rep. 2023;13(1):6952. https:\/\/doi.org\/10.1038\/s41598-023-33128-9.","journal-title":"Sci Rep"},{"issue":"1","key":"980_CR50","doi-asserted-by":"publisher","first-page":"1710899","DOI":"10.1080\/20013078.2019.1710899","volume":"9","author":"M Cordonnier","year":"2020","unstructured":"Cordonnier M, Nardin C, Chanteloup G, Derangere V, Algros MP, Arnould L, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicle. 2020;9(1):1710899. https:\/\/doi.org\/10.1080\/20013078.2019.1710899.","journal-title":"J Extracell Vesicle"},{"issue":"9","key":"980_CR51","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1111\/cas.15033","volume":"112","author":"J Chen","year":"2021","unstructured":"Chen J, Song Y, Miao F, Chen G, Zhu Y, Wu N, et al. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8 + T cell exhaustion during metastasis. Cancer Sci. 2021;112(9):3437\u201354. https:\/\/doi.org\/10.1111\/cas.15033.","journal-title":"Cancer Sci"},{"issue":"4","key":"980_CR52","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","volume":"29","author":"MJ Cox","year":"2021","unstructured":"Cox MJ, Lucien F, Sakemura R, Boysen JC, Kim Y, Horvei P, et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther. 2021;29(4):1529\u201340. https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.033.","journal-title":"Mol Ther"},{"issue":"5","key":"980_CR53","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.7150\/thno.47996","volume":"11","author":"C Tu","year":"2021","unstructured":"Tu C, Du Z, Zhang H, Feng Y, Qi Y, Zheng Y, et al. Endocytic pathway inhibition attenuates extracellular vesicle-induced reduction of chemosensitivity to bortezomib in multiple myeloma cells. Theranostics. 2021;11(5):2364\u201380. https:\/\/doi.org\/10.7150\/thno.47996.","journal-title":"Theranostics"},{"issue":"16","key":"980_CR54","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1158\/0008-5472.CAN-22-2220","volume":"83","author":"W Zhong","year":"2023","unstructured":"Zhong W, Xiao Z, Qin Z, Yang J, Wen Y, Yu Z, et al. Tumor-derived Small extracellular vesicles inhibit the efficacy of CAR T cells against solid tumors. Cancer Res. 2023;83(16):2790\u2013806. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2220.","journal-title":"Cancer Res"},{"issue":"7","key":"980_CR55","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s43018-025-00949-8","volume":"6","author":"W Zhong","year":"2025","unstructured":"Zhong W, Qin Z, Yu Z, Yang J, Yan D, Engel NW, et al. Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors. Nat Cancer. 2025;6(7):1157\u201372. https:\/\/doi.org\/10.1038\/s43018-025-00949-8.","journal-title":"Nat Cancer"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00980-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00980-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:17:43Z","timestamp":1788275863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00980-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["980"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00980-6","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving human participants were reviewed and approved by ethics committee of the Affiliated Hospital of Xuzhou Medical University, and the Third Affiliated Hospital of Soochow University. Written informed consent was obtained from all participants prior to their inclusion in the study. The animal studies were approved by the Experimental Animal Ethics Committee of Xuzhou Medical University and were performed in accordance with institutional guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"115"}}